"Any sufficiently advanced technology is indistinguishable from magic." — I invest in making that magic real. Focused purely on the shift from Science Fiction to Science Fact. No specific sector. Just paradigm shifts.
https://x.com/TalosTheGiant
5E Advanced Materials (FEAM): A Binary Critical Minerals Play with a $6.65 Fair Value Target
The Valuation Model: The Math Behind the $6.65 Target Our valuation is built on a theoretical 2031 "Bull Case" scenario, assuming the successful execution of Commercial Phase 1 and the initiation of Phase 2 at the Fort Cady facility. 2031 Projected Revenue: $550,000,000 USD (Driven by core boric acid production and a ~20% shift into high-margin advanced derivatives like Meta Boric Acid and Ferroboron).Read more
The "Landlord of Orbit" – A Deep Value Play Ahead of the Starlab Era
Voyager Technologies presents a unique arbitrage opportunity. The market is currently pricing it as a low-growth defense contractor (based on its Q3 revenue of ~$40M), completely ignoring the massive "hidden asset" on its balance sheet: Starlab.Read more
The "Rate Cut" Supercycle Winner – Profitable & Accelerating
Pagaya Technologies is entering a "Goldilocks" scenario. For the last two years, it operated under high interest rates, which compressed margins.Read more
The Industrialist of the Skies – Scaling with "Automotive DNA
Archer Aviation is positioned to be the first to scale in the trillion-dollar Urban Air Mobility (UAM) market. Unlike competitors struggling with "production hell," Archer has solved the manufacturing equation through its strategic partnership with Stellantis , which is funding and building Archer's high-volume factory in Georgia.Read more
The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)
Evaxion Biotech is a micro-cap TechBio company punching significantly above its weight class. While the market views it as a small preclinical player, its proprietary AI-Immunology™ platform has already secured a massive validation: a partnership with Merck (MSD).Read more
Moving from "Science Fiction" to "Science Fact" – A Bullish Valuation Case
Recursion Pharmaceuticals is currently at a critical inflection point. For years, the company was viewed as a "science project"—a high-tech platform promising to revolutionize drug discovery with AI.Read more
Efficiency is the New Growth: Dynatrace is the Ultimate "Consolidation" Play
The market currently prices Dynatrace as a "Steady Eddie" in the observability space, overshadowing the massive transformation occurring under the hood. While competitors chase "growth at all costs," Dynatrace has positioned itself as the "CFO’s Choice"—the only platform capable of delivering massive cost savings through tool consolidation while offering the most precise AI for the Global 1000.Read more
The "David vs. Goliath" AI Trade – Why Second Place is Worth Billions
While Nvidia captures the headlines, AMD is capturing the "spillover." The AI accelerator market is projected to reach $400 Billion by 2027. AMD does not need to beat Nvidia to win; it only needs to capture 10-20% of this massive TAM (Total Addressable Market).Read more
The "Physical AI" Monopoly – A New Industrial Revolution
Tesla ($TSLA) has officially exited the automotive peer group. By dismantling legacy Model S/X lines to build humanoid robots, the company has declared its transition from a car manufacturer to the world’s first "Physical AI" platform.Read more